mouse pd l1  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92
    Name:
    PD L1 Protein Mouse Recombinant
    Description:
    A DNA sequence encoding the mouse Cd274 NP 068693 1 Met1 His239 was expressed with the Fc region of human IgG1 at the C terminus
    Catalog Number:
    50010-M02H
    Price:
    None
    Category:
    recombinant protein
    Product Aliases:
    A530045L16Rik Protein Mouse, B7h1 Protein Mouse, Pdcd1l1 Protein Mouse, Pdcd1lg1 Protein Mouse, Pdl1 Protein Mouse
    Host:
    HEK293 Cells
    Buy from Supplier


    Structured Review

    Sino Biological mouse pd l1
    89 Zr-C4 can specifically detect mouse <t>PD-L1</t> in tumors established in an immunocompetent background. (A) Representative coronal and transaxial PET/CT images of male C57BL/6 mice bearing subcutaneous B16 F10 tumors, a mouse model of melanoma, show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 10-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P
    A DNA sequence encoding the mouse Cd274 NP 068693 1 Met1 His239 was expressed with the Fc region of human IgG1 at the C terminus
    https://www.bioz.com/result/mouse pd l1/product/Sino Biological
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse pd l1 - by Bioz Stars, 2021-07
    92/100 stars

    Images

    1) Product Images from "Imaging PD-L1 Expression with ImmunoPET"

    Article Title: Imaging PD-L1 Expression with ImmunoPET

    Journal: Bioconjugate Chemistry

    doi: 10.1021/acs.bioconjchem.7b00631

    89 Zr-C4 can specifically detect mouse PD-L1 in tumors established in an immunocompetent background. (A) Representative coronal and transaxial PET/CT images of male C57BL/6 mice bearing subcutaneous B16 F10 tumors, a mouse model of melanoma, show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 10-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P
    Figure Legend Snippet: 89 Zr-C4 can specifically detect mouse PD-L1 in tumors established in an immunocompetent background. (A) Representative coronal and transaxial PET/CT images of male C57BL/6 mice bearing subcutaneous B16 F10 tumors, a mouse model of melanoma, show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 10-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P

    Techniques Used: Positron Emission Tomography, Mouse Assay, Injection, Blocking Assay

    89 Zr-C4 can detect pharmacologically induced PD-L1 expression changes on the tumor cell. (A) Representative coronal and transverse PET images showing the distribution of 89 Zr-C4 48 h after injection in a cohort of male nu/nu mice bearing subcutaneous H1975 xenografts and treated with vehicle, paclitaxel (Taxol), or doxorubicine. The mice were treated with 20 mg/kg paclitaxel or 2 mg/kg doxorubicine for 2 days prior to radiotracer injection. (B) Representative biodistribution data in the tumor and selected normal tissues showing that paclitaxel increases tumor PD-L1 expression levels, while doxorubicin suppresses it compared to vehicle. No impact was observed on PD-L1 expressing normal tissues like liver and spleen. (∗) P
    Figure Legend Snippet: 89 Zr-C4 can detect pharmacologically induced PD-L1 expression changes on the tumor cell. (A) Representative coronal and transverse PET images showing the distribution of 89 Zr-C4 48 h after injection in a cohort of male nu/nu mice bearing subcutaneous H1975 xenografts and treated with vehicle, paclitaxel (Taxol), or doxorubicine. The mice were treated with 20 mg/kg paclitaxel or 2 mg/kg doxorubicine for 2 days prior to radiotracer injection. (B) Representative biodistribution data in the tumor and selected normal tissues showing that paclitaxel increases tumor PD-L1 expression levels, while doxorubicin suppresses it compared to vehicle. No impact was observed on PD-L1 expressing normal tissues like liver and spleen. (∗) P

    Techniques Used: Expressing, Positron Emission Tomography, Injection, Mouse Assay

    Defining the optimal time after injection to study PD-L1 expression levels in a xenograft model. (A) Representative coronal and transaxial PET/CT images of male nu/nu mice bearing subcutaneous H1975 tumors, a human model of NSCLC , show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 30-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P
    Figure Legend Snippet: Defining the optimal time after injection to study PD-L1 expression levels in a xenograft model. (A) Representative coronal and transaxial PET/CT images of male nu/nu mice bearing subcutaneous H1975 tumors, a human model of NSCLC , show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 30-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P

    Techniques Used: Injection, Expressing, Positron Emission Tomography, Mouse Assay, Blocking Assay

    89 Zr-C4 detects PD-L1 expression levels in a PDX derived from a NSCLC patient that experienced a durable clinical response to anti-PD-1 and anti-CTLA4 therapies. (A) Transaxial CT slices showing a soft tissue lesion in the lung prior to the initiation of pembrolizumab and ipilimumab (left), and a smaller mass 3 months after the start of therapy (right). The position of the tumor is indicated with a white arrow. This patient experienced a partial response for 8 months. The PDX was derived 7 months prior to the first CT scan. (B) Small animal PET/CT data showing the biodistribution of 89 Zr-C4 in mice bearing bilateral PDX tumors in the flank. The tumors can be clearly resolved, and radiotracer uptake in abdominal tissues like the liver is observed, as expected for a large biomolecule. Mice treated with 89 Zr-C4 that was heat denatured (HD) for 10 min prior to injection show no evidence of radiotracer uptake in the tumor. (C) Biodistribution data showing the uptake of 89 Zr-C4 in the PDX tissue 48 h after injection. The uptake is higher in the tumor compared to heat denatured 89 Zr-C4 (HD) and standard reference tissues like the blood and muscle. (D) Biodistribution data acquired 48 h after injection in mice bearing subcutaneous H1975, PC3, A549, and the PDX tumors show the different degree of 89 Zr-C4 uptake in the tumors.
    Figure Legend Snippet: 89 Zr-C4 detects PD-L1 expression levels in a PDX derived from a NSCLC patient that experienced a durable clinical response to anti-PD-1 and anti-CTLA4 therapies. (A) Transaxial CT slices showing a soft tissue lesion in the lung prior to the initiation of pembrolizumab and ipilimumab (left), and a smaller mass 3 months after the start of therapy (right). The position of the tumor is indicated with a white arrow. This patient experienced a partial response for 8 months. The PDX was derived 7 months prior to the first CT scan. (B) Small animal PET/CT data showing the biodistribution of 89 Zr-C4 in mice bearing bilateral PDX tumors in the flank. The tumors can be clearly resolved, and radiotracer uptake in abdominal tissues like the liver is observed, as expected for a large biomolecule. Mice treated with 89 Zr-C4 that was heat denatured (HD) for 10 min prior to injection show no evidence of radiotracer uptake in the tumor. (C) Biodistribution data showing the uptake of 89 Zr-C4 in the PDX tissue 48 h after injection. The uptake is higher in the tumor compared to heat denatured 89 Zr-C4 (HD) and standard reference tissues like the blood and muscle. (D) Biodistribution data acquired 48 h after injection in mice bearing subcutaneous H1975, PC3, A549, and the PDX tumors show the different degree of 89 Zr-C4 uptake in the tumors.

    Techniques Used: Expressing, Derivative Assay, Computed Tomography, Positron Emission Tomography, Mouse Assay, Injection

    2) Product Images from "Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers"

    Article Title: Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers

    Journal: Oncotarget

    doi: 10.18632/oncotarget.16708

    Selection of anti-mouse-PD-L1 specific Nbs ( A ) Amino acid sequence alignment of the purified Nbs C3, C7, E2 and E4. The Nb sequence includes three complementarity-determining regions (CDR 1, 2, 3; indicated in red) and four framework regions (FR1-4, indicated in black). FRs are relatively conserved but CDRs vary widely among Nbs. ( B ) Affinity/kinetics SPR study of purified Nbs interacting with immobilized His-tagged recombinant mouse PD-L1 protein. Sensorgrams of different concentrations of the Nbs are shown ( n  = 1). ( C ) Representative flow cytometry results, showing staining of unmodified HEK293T cells (grey line) or HEK293T cells lentivirally modified to express mouse PD-L1 (293T moPD-L1, red line) with mAbs specific for mouse PD-L1 or Nbs C3, C7, E4 and E2 ( n  = 3).
    Figure Legend Snippet: Selection of anti-mouse-PD-L1 specific Nbs ( A ) Amino acid sequence alignment of the purified Nbs C3, C7, E2 and E4. The Nb sequence includes three complementarity-determining regions (CDR 1, 2, 3; indicated in red) and four framework regions (FR1-4, indicated in black). FRs are relatively conserved but CDRs vary widely among Nbs. ( B ) Affinity/kinetics SPR study of purified Nbs interacting with immobilized His-tagged recombinant mouse PD-L1 protein. Sensorgrams of different concentrations of the Nbs are shown ( n = 1). ( C ) Representative flow cytometry results, showing staining of unmodified HEK293T cells (grey line) or HEK293T cells lentivirally modified to express mouse PD-L1 (293T moPD-L1, red line) with mAbs specific for mouse PD-L1 or Nbs C3, C7, E4 and E2 ( n = 3).

    Techniques Used: Selection, Sequencing, Purification, SPR Assay, Recombinant, Flow Cytometry, Cytometry, Staining, Modification

    3) Product Images from "Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers"

    Article Title: Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers

    Journal: Oncotarget

    doi: 10.18632/oncotarget.16708

    Selection of anti-mouse-PD-L1 specific Nbs ( A ) Amino acid sequence alignment of the purified Nbs C3, C7, E2 and E4. The Nb sequence includes three complementarity-determining regions (CDR 1, 2, 3; indicated in red) and four framework regions (FR1-4, indicated in black). FRs are relatively conserved but CDRs vary widely among Nbs. ( B ) Affinity/kinetics SPR study of purified Nbs interacting with immobilized His-tagged recombinant mouse PD-L1 protein. Sensorgrams of different concentrations of the Nbs are shown ( n  = 1). ( C ) Representative flow cytometry results, showing staining of unmodified HEK293T cells (grey line) or HEK293T cells lentivirally modified to express mouse PD-L1 (293T moPD-L1, red line) with mAbs specific for mouse PD-L1 or Nbs C3, C7, E4 and E2 ( n  = 3).
    Figure Legend Snippet: Selection of anti-mouse-PD-L1 specific Nbs ( A ) Amino acid sequence alignment of the purified Nbs C3, C7, E2 and E4. The Nb sequence includes three complementarity-determining regions (CDR 1, 2, 3; indicated in red) and four framework regions (FR1-4, indicated in black). FRs are relatively conserved but CDRs vary widely among Nbs. ( B ) Affinity/kinetics SPR study of purified Nbs interacting with immobilized His-tagged recombinant mouse PD-L1 protein. Sensorgrams of different concentrations of the Nbs are shown ( n = 1). ( C ) Representative flow cytometry results, showing staining of unmodified HEK293T cells (grey line) or HEK293T cells lentivirally modified to express mouse PD-L1 (293T moPD-L1, red line) with mAbs specific for mouse PD-L1 or Nbs C3, C7, E4 and E2 ( n = 3).

    Techniques Used: Selection, Sequencing, Purification, SPR Assay, Recombinant, Flow Cytometry, Cytometry, Staining, Modification

    4) Product Images from "Imaging PD-L1 Expression with ImmunoPET"

    Article Title: Imaging PD-L1 Expression with ImmunoPET

    Journal: Bioconjugate Chemistry

    doi: 10.1021/acs.bioconjchem.7b00631

    89 Zr-C4 can specifically detect mouse PD-L1 in tumors established in an immunocompetent background. (A) Representative coronal and transaxial PET/CT images of male C57BL/6 mice bearing subcutaneous B16 F10 tumors, a mouse model of melanoma, show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 10-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P
    Figure Legend Snippet: 89 Zr-C4 can specifically detect mouse PD-L1 in tumors established in an immunocompetent background. (A) Representative coronal and transaxial PET/CT images of male C57BL/6 mice bearing subcutaneous B16 F10 tumors, a mouse model of melanoma, show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 10-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P

    Techniques Used: Positron Emission Tomography, Mouse Assay, Injection, Blocking Assay

    89 Zr-C4 can detect pharmacologically induced PD-L1 expression changes on the tumor cell. (A) Representative coronal and transverse PET images showing the distribution of 89 Zr-C4 48 h after injection in a cohort of male nu/nu mice bearing subcutaneous H1975 xenografts and treated with vehicle, paclitaxel (Taxol), or doxorubicine. The mice were treated with 20 mg/kg paclitaxel or 2 mg/kg doxorubicine for 2 days prior to radiotracer injection. (B) Representative biodistribution data in the tumor and selected normal tissues showing that paclitaxel increases tumor PD-L1 expression levels, while doxorubicin suppresses it compared to vehicle. No impact was observed on PD-L1 expressing normal tissues like liver and spleen. (∗) P
    Figure Legend Snippet: 89 Zr-C4 can detect pharmacologically induced PD-L1 expression changes on the tumor cell. (A) Representative coronal and transverse PET images showing the distribution of 89 Zr-C4 48 h after injection in a cohort of male nu/nu mice bearing subcutaneous H1975 xenografts and treated with vehicle, paclitaxel (Taxol), or doxorubicine. The mice were treated with 20 mg/kg paclitaxel or 2 mg/kg doxorubicine for 2 days prior to radiotracer injection. (B) Representative biodistribution data in the tumor and selected normal tissues showing that paclitaxel increases tumor PD-L1 expression levels, while doxorubicin suppresses it compared to vehicle. No impact was observed on PD-L1 expressing normal tissues like liver and spleen. (∗) P

    Techniques Used: Expressing, Positron Emission Tomography, Injection, Mouse Assay

    Defining the optimal time after injection to study PD-L1 expression levels in a xenograft model. (A) Representative coronal and transaxial PET/CT images of male nu/nu mice bearing subcutaneous H1975 tumors, a human model of NSCLC , show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 30-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P
    Figure Legend Snippet: Defining the optimal time after injection to study PD-L1 expression levels in a xenograft model. (A) Representative coronal and transaxial PET/CT images of male nu/nu mice bearing subcutaneous H1975 tumors, a human model of NSCLC , show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 30-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P

    Techniques Used: Injection, Expressing, Positron Emission Tomography, Mouse Assay, Blocking Assay

    89 Zr-C4 detects PD-L1 expression levels in a PDX derived from a NSCLC patient that experienced a durable clinical response to anti-PD-1 and anti-CTLA4 therapies. (A) Transaxial CT slices showing a soft tissue lesion in the lung prior to the initiation of pembrolizumab and ipilimumab (left), and a smaller mass 3 months after the start of therapy (right). The position of the tumor is indicated with a white arrow. This patient experienced a partial response for 8 months. The PDX was derived 7 months prior to the first CT scan. (B) Small animal PET/CT data showing the biodistribution of 89 Zr-C4 in mice bearing bilateral PDX tumors in the flank. The tumors can be clearly resolved, and radiotracer uptake in abdominal tissues like the liver is observed, as expected for a large biomolecule. Mice treated with 89 Zr-C4 that was heat denatured (HD) for 10 min prior to injection show no evidence of radiotracer uptake in the tumor. (C) Biodistribution data showing the uptake of 89 Zr-C4 in the PDX tissue 48 h after injection. The uptake is higher in the tumor compared to heat denatured 89 Zr-C4 (HD) and standard reference tissues like the blood and muscle. (D) Biodistribution data acquired 48 h after injection in mice bearing subcutaneous H1975, PC3, A549, and the PDX tumors show the different degree of 89 Zr-C4 uptake in the tumors.
    Figure Legend Snippet: 89 Zr-C4 detects PD-L1 expression levels in a PDX derived from a NSCLC patient that experienced a durable clinical response to anti-PD-1 and anti-CTLA4 therapies. (A) Transaxial CT slices showing a soft tissue lesion in the lung prior to the initiation of pembrolizumab and ipilimumab (left), and a smaller mass 3 months after the start of therapy (right). The position of the tumor is indicated with a white arrow. This patient experienced a partial response for 8 months. The PDX was derived 7 months prior to the first CT scan. (B) Small animal PET/CT data showing the biodistribution of 89 Zr-C4 in mice bearing bilateral PDX tumors in the flank. The tumors can be clearly resolved, and radiotracer uptake in abdominal tissues like the liver is observed, as expected for a large biomolecule. Mice treated with 89 Zr-C4 that was heat denatured (HD) for 10 min prior to injection show no evidence of radiotracer uptake in the tumor. (C) Biodistribution data showing the uptake of 89 Zr-C4 in the PDX tissue 48 h after injection. The uptake is higher in the tumor compared to heat denatured 89 Zr-C4 (HD) and standard reference tissues like the blood and muscle. (D) Biodistribution data acquired 48 h after injection in mice bearing subcutaneous H1975, PC3, A549, and the PDX tumors show the different degree of 89 Zr-C4 uptake in the tumors.

    Techniques Used: Expressing, Derivative Assay, Computed Tomography, Positron Emission Tomography, Mouse Assay, Injection

    5) Product Images from "A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model"

    Article Title: A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model

    Journal: Molecular Therapy Oncolytics

    doi: 10.1016/j.omto.2019.06.002

    The CTL Response Induced by DPDL1E Vaccination (A) Lymphocytes from spleens of DPDL1E- and DTT-immunized mice were used as effector cells. PD-L1-positive expressed B16-F10 cells were used as target cells. Cytotoxicity was assessed with an LDH release assay. Statistically significant differences were determined using Student’s t test. (B) Lymphocytes isolated from DTT- and DPDL1E-immunized mice were stimulated with His-PD-L1 recombinant protein or Con A for 72 h. Cell proliferation was measured with the CCK-8 method. (C) The concentrations of TNF-α, IFN-γ, and IL-2 in supernatant after 72 h stimulation. The cytokines were detected using an ELISA kit. Anti-CD3/CD28 beads (0.5 μg/mL) were used as a positive control. (D) Proliferation of T cells was determined using a CFSE-based assay  in vitro . CD8+ and CD4+ T cells were gated and analyzed using FCM. Both CD8+ and CD4+ T cells proliferated more than the DTT control group after His-PD-L1 stimulation. Statistically significant differences were calculated by Student’s t test. NS, not significant; *p 
    Figure Legend Snippet: The CTL Response Induced by DPDL1E Vaccination (A) Lymphocytes from spleens of DPDL1E- and DTT-immunized mice were used as effector cells. PD-L1-positive expressed B16-F10 cells were used as target cells. Cytotoxicity was assessed with an LDH release assay. Statistically significant differences were determined using Student’s t test. (B) Lymphocytes isolated from DTT- and DPDL1E-immunized mice were stimulated with His-PD-L1 recombinant protein or Con A for 72 h. Cell proliferation was measured with the CCK-8 method. (C) The concentrations of TNF-α, IFN-γ, and IL-2 in supernatant after 72 h stimulation. The cytokines were detected using an ELISA kit. Anti-CD3/CD28 beads (0.5 μg/mL) were used as a positive control. (D) Proliferation of T cells was determined using a CFSE-based assay in vitro . CD8+ and CD4+ T cells were gated and analyzed using FCM. Both CD8+ and CD4+ T cells proliferated more than the DTT control group after His-PD-L1 stimulation. Statistically significant differences were calculated by Student’s t test. NS, not significant; *p 

    Techniques Used: Mouse Assay, Lactate Dehydrogenase Assay, Isolation, Recombinant, CCK-8 Assay, Enzyme-linked Immunosorbent Assay, Positive Control, CFSE Assay

    6) Product Images from "Imaging PD-L1 Expression with ImmunoPET"

    Article Title: Imaging PD-L1 Expression with ImmunoPET

    Journal: Bioconjugate Chemistry

    doi: 10.1021/acs.bioconjchem.7b00631

    89 Zr-C4 can specifically detect mouse PD-L1 in tumors established in an immunocompetent background. (A) Representative coronal and transaxial PET/CT images of male C57BL/6 mice bearing subcutaneous B16 F10 tumors, a mouse model of melanoma, show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 10-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P
    Figure Legend Snippet: 89 Zr-C4 can specifically detect mouse PD-L1 in tumors established in an immunocompetent background. (A) Representative coronal and transaxial PET/CT images of male C57BL/6 mice bearing subcutaneous B16 F10 tumors, a mouse model of melanoma, show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 10-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P

    Techniques Used: Positron Emission Tomography, Mouse Assay, Injection, Blocking Assay

    89 Zr-C4 can detect pharmacologically induced PD-L1 expression changes on the tumor cell. (A) Representative coronal and transverse PET images showing the distribution of 89 Zr-C4 48 h after injection in a cohort of male nu/nu mice bearing subcutaneous H1975 xenografts and treated with vehicle, paclitaxel (Taxol), or doxorubicine. The mice were treated with 20 mg/kg paclitaxel or 2 mg/kg doxorubicine for 2 days prior to radiotracer injection. (B) Representative biodistribution data in the tumor and selected normal tissues showing that paclitaxel increases tumor PD-L1 expression levels, while doxorubicin suppresses it compared to vehicle. No impact was observed on PD-L1 expressing normal tissues like liver and spleen. (∗) P
    Figure Legend Snippet: 89 Zr-C4 can detect pharmacologically induced PD-L1 expression changes on the tumor cell. (A) Representative coronal and transverse PET images showing the distribution of 89 Zr-C4 48 h after injection in a cohort of male nu/nu mice bearing subcutaneous H1975 xenografts and treated with vehicle, paclitaxel (Taxol), or doxorubicine. The mice were treated with 20 mg/kg paclitaxel or 2 mg/kg doxorubicine for 2 days prior to radiotracer injection. (B) Representative biodistribution data in the tumor and selected normal tissues showing that paclitaxel increases tumor PD-L1 expression levels, while doxorubicin suppresses it compared to vehicle. No impact was observed on PD-L1 expressing normal tissues like liver and spleen. (∗) P

    Techniques Used: Expressing, Positron Emission Tomography, Injection, Mouse Assay

    Defining the optimal time after injection to study PD-L1 expression levels in a xenograft model. (A) Representative coronal and transaxial PET/CT images of male nu/nu mice bearing subcutaneous H1975 tumors, a human model of NSCLC , show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 30-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P
    Figure Legend Snippet: Defining the optimal time after injection to study PD-L1 expression levels in a xenograft model. (A) Representative coronal and transaxial PET/CT images of male nu/nu mice bearing subcutaneous H1975 tumors, a human model of NSCLC , show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 30-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P

    Techniques Used: Injection, Expressing, Positron Emission Tomography, Mouse Assay, Blocking Assay

    89 Zr-C4 detects PD-L1 expression levels in a PDX derived from a NSCLC patient that experienced a durable clinical response to anti-PD-1 and anti-CTLA4 therapies. (A) Transaxial CT slices showing a soft tissue lesion in the lung prior to the initiation of pembrolizumab and ipilimumab (left), and a smaller mass 3 months after the start of therapy (right). The position of the tumor is indicated with a white arrow. This patient experienced a partial response for 8 months. The PDX was derived 7 months prior to the first CT scan. (B) Small animal PET/CT data showing the biodistribution of 89 Zr-C4 in mice bearing bilateral PDX tumors in the flank. The tumors can be clearly resolved, and radiotracer uptake in abdominal tissues like the liver is observed, as expected for a large biomolecule. Mice treated with 89 Zr-C4 that was heat denatured (HD) for 10 min prior to injection show no evidence of radiotracer uptake in the tumor. (C) Biodistribution data showing the uptake of 89 Zr-C4 in the PDX tissue 48 h after injection. The uptake is higher in the tumor compared to heat denatured 89 Zr-C4 (HD) and standard reference tissues like the blood and muscle. (D) Biodistribution data acquired 48 h after injection in mice bearing subcutaneous H1975, PC3, A549, and the PDX tumors show the different degree of 89 Zr-C4 uptake in the tumors.
    Figure Legend Snippet: 89 Zr-C4 detects PD-L1 expression levels in a PDX derived from a NSCLC patient that experienced a durable clinical response to anti-PD-1 and anti-CTLA4 therapies. (A) Transaxial CT slices showing a soft tissue lesion in the lung prior to the initiation of pembrolizumab and ipilimumab (left), and a smaller mass 3 months after the start of therapy (right). The position of the tumor is indicated with a white arrow. This patient experienced a partial response for 8 months. The PDX was derived 7 months prior to the first CT scan. (B) Small animal PET/CT data showing the biodistribution of 89 Zr-C4 in mice bearing bilateral PDX tumors in the flank. The tumors can be clearly resolved, and radiotracer uptake in abdominal tissues like the liver is observed, as expected for a large biomolecule. Mice treated with 89 Zr-C4 that was heat denatured (HD) for 10 min prior to injection show no evidence of radiotracer uptake in the tumor. (C) Biodistribution data showing the uptake of 89 Zr-C4 in the PDX tissue 48 h after injection. The uptake is higher in the tumor compared to heat denatured 89 Zr-C4 (HD) and standard reference tissues like the blood and muscle. (D) Biodistribution data acquired 48 h after injection in mice bearing subcutaneous H1975, PC3, A549, and the PDX tumors show the different degree of 89 Zr-C4 uptake in the tumors.

    Techniques Used: Expressing, Derivative Assay, Computed Tomography, Positron Emission Tomography, Mouse Assay, Injection

    7) Product Images from "Imaging PD-L1 Expression with ImmunoPET"

    Article Title: Imaging PD-L1 Expression with ImmunoPET

    Journal: Bioconjugate Chemistry

    doi: 10.1021/acs.bioconjchem.7b00631

    89 Zr-C4 can specifically detect mouse PD-L1 in tumors established in an immunocompetent background. (A) Representative coronal and transaxial PET/CT images of male C57BL/6 mice bearing subcutaneous B16 F10 tumors, a mouse model of melanoma, show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 10-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P
    Figure Legend Snippet: 89 Zr-C4 can specifically detect mouse PD-L1 in tumors established in an immunocompetent background. (A) Representative coronal and transaxial PET/CT images of male C57BL/6 mice bearing subcutaneous B16 F10 tumors, a mouse model of melanoma, show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 10-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P

    Techniques Used: Positron Emission Tomography, Mouse Assay, Injection, Blocking Assay

    89 Zr-C4 can detect pharmacologically induced PD-L1 expression changes on the tumor cell. (A) Representative coronal and transverse PET images showing the distribution of 89 Zr-C4 48 h after injection in a cohort of male nu/nu mice bearing subcutaneous H1975 xenografts and treated with vehicle, paclitaxel (Taxol), or doxorubicine. The mice were treated with 20 mg/kg paclitaxel or 2 mg/kg doxorubicine for 2 days prior to radiotracer injection. (B) Representative biodistribution data in the tumor and selected normal tissues showing that paclitaxel increases tumor PD-L1 expression levels, while doxorubicin suppresses it compared to vehicle. No impact was observed on PD-L1 expressing normal tissues like liver and spleen. (∗) P
    Figure Legend Snippet: 89 Zr-C4 can detect pharmacologically induced PD-L1 expression changes on the tumor cell. (A) Representative coronal and transverse PET images showing the distribution of 89 Zr-C4 48 h after injection in a cohort of male nu/nu mice bearing subcutaneous H1975 xenografts and treated with vehicle, paclitaxel (Taxol), or doxorubicine. The mice were treated with 20 mg/kg paclitaxel or 2 mg/kg doxorubicine for 2 days prior to radiotracer injection. (B) Representative biodistribution data in the tumor and selected normal tissues showing that paclitaxel increases tumor PD-L1 expression levels, while doxorubicin suppresses it compared to vehicle. No impact was observed on PD-L1 expressing normal tissues like liver and spleen. (∗) P

    Techniques Used: Expressing, Positron Emission Tomography, Injection, Mouse Assay

    Defining the optimal time after injection to study PD-L1 expression levels in a xenograft model. (A) Representative coronal and transaxial PET/CT images of male nu/nu mice bearing subcutaneous H1975 tumors, a human model of NSCLC , show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 30-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P
    Figure Legend Snippet: Defining the optimal time after injection to study PD-L1 expression levels in a xenograft model. (A) Representative coronal and transaxial PET/CT images of male nu/nu mice bearing subcutaneous H1975 tumors, a human model of NSCLC , show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 30-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P

    Techniques Used: Injection, Expressing, Positron Emission Tomography, Mouse Assay, Blocking Assay

    89 Zr-C4 detects PD-L1 expression levels in a PDX derived from a NSCLC patient that experienced a durable clinical response to anti-PD-1 and anti-CTLA4 therapies. (A) Transaxial CT slices showing a soft tissue lesion in the lung prior to the initiation of pembrolizumab and ipilimumab (left), and a smaller mass 3 months after the start of therapy (right). The position of the tumor is indicated with a white arrow. This patient experienced a partial response for 8 months. The PDX was derived 7 months prior to the first CT scan. (B) Small animal PET/CT data showing the biodistribution of 89 Zr-C4 in mice bearing bilateral PDX tumors in the flank. The tumors can be clearly resolved, and radiotracer uptake in abdominal tissues like the liver is observed, as expected for a large biomolecule. Mice treated with 89 Zr-C4 that was heat denatured (HD) for 10 min prior to injection show no evidence of radiotracer uptake in the tumor. (C) Biodistribution data showing the uptake of 89 Zr-C4 in the PDX tissue 48 h after injection. The uptake is higher in the tumor compared to heat denatured 89 Zr-C4 (HD) and standard reference tissues like the blood and muscle. (D) Biodistribution data acquired 48 h after injection in mice bearing subcutaneous H1975, PC3, A549, and the PDX tumors show the different degree of 89 Zr-C4 uptake in the tumors.
    Figure Legend Snippet: 89 Zr-C4 detects PD-L1 expression levels in a PDX derived from a NSCLC patient that experienced a durable clinical response to anti-PD-1 and anti-CTLA4 therapies. (A) Transaxial CT slices showing a soft tissue lesion in the lung prior to the initiation of pembrolizumab and ipilimumab (left), and a smaller mass 3 months after the start of therapy (right). The position of the tumor is indicated with a white arrow. This patient experienced a partial response for 8 months. The PDX was derived 7 months prior to the first CT scan. (B) Small animal PET/CT data showing the biodistribution of 89 Zr-C4 in mice bearing bilateral PDX tumors in the flank. The tumors can be clearly resolved, and radiotracer uptake in abdominal tissues like the liver is observed, as expected for a large biomolecule. Mice treated with 89 Zr-C4 that was heat denatured (HD) for 10 min prior to injection show no evidence of radiotracer uptake in the tumor. (C) Biodistribution data showing the uptake of 89 Zr-C4 in the PDX tissue 48 h after injection. The uptake is higher in the tumor compared to heat denatured 89 Zr-C4 (HD) and standard reference tissues like the blood and muscle. (D) Biodistribution data acquired 48 h after injection in mice bearing subcutaneous H1975, PC3, A549, and the PDX tumors show the different degree of 89 Zr-C4 uptake in the tumors.

    Techniques Used: Expressing, Derivative Assay, Computed Tomography, Positron Emission Tomography, Mouse Assay, Injection

    8) Product Images from "PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways"

    Article Title: PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways

    Journal: Immunity

    doi: 10.1016/j.immuni.2019.11.003

    PD-L1 Binds CD80 in Cis , and Atezolizumab Disrupts this Interaction (A) Representative TIRF images of PD-L1 LUVs captured by PD-1 SLB, CD80 SLB, or CD86 SLB; each LUV is registered as a green spot. Bar graph summarizes the fluorescence intensity (FI) of the LUV channel under indicated conditions, normalized to the intensity of the condition with PD-1 SLBs. Data are means ± SEM, n = 3. Scale bars, 5 μm. (B) A FRET assay showing PD-L1:CD80 cis -interaction on cell membranes. Cartoons on the left depict a HEK293T cell co-expressing PD-L1 (labeled with CS547, donor) and either CD80 or CD86 (labeled with SSAF647, acceptor). On the immediate right are pre- and post-bleaching confocal images of a representative cell at the indicated channels. Further right are calculated FRET efficiency images (pseudo-color; the yellow to purple spectrum denotes strong to weak FRET) and the differential interference contrast (DIC) images. Rightmost are bar graphs summarizing the FRET efficiencies as mean ± SEM, n > 25 cells from 3 independent experiments. Scale bars, 10 μm. (C) Same as (B) except replacing PD-L1 with PD-L2. (D) On the left is a cartoon depicting an LUV FRET assay for probing PD-L1:CD80 cis -interaction and atezolizumab (Atezo) effects. SC505 (donor) labeled SNAP-PD-L1-His was pre-bound to LUVs via DGS-NTA-Ni. Subsequently added TMR (acceptor) labeled SNAP-CD80-His bound to the LUVs and interacted with PD-L1 in cis , causing FRET and SC505 quenching (black trace). On the right are time courses of normalized SC505 fluorescence under the indicated conditions. Color coding is as follows: blue, same as black except plus atezolizumab; magenta, same as black except using TMR*CD80 lacking a His tag; orange, same as black except replacing PD-L1 with PD-L2; gray, same as black except presenting TMR*CD80 in trans . Data are representative of 3 independent replicates. Unpaired two-tailed Student’s t test: *p
    Figure Legend Snippet: PD-L1 Binds CD80 in Cis , and Atezolizumab Disrupts this Interaction (A) Representative TIRF images of PD-L1 LUVs captured by PD-1 SLB, CD80 SLB, or CD86 SLB; each LUV is registered as a green spot. Bar graph summarizes the fluorescence intensity (FI) of the LUV channel under indicated conditions, normalized to the intensity of the condition with PD-1 SLBs. Data are means ± SEM, n = 3. Scale bars, 5 μm. (B) A FRET assay showing PD-L1:CD80 cis -interaction on cell membranes. Cartoons on the left depict a HEK293T cell co-expressing PD-L1 (labeled with CS547, donor) and either CD80 or CD86 (labeled with SSAF647, acceptor). On the immediate right are pre- and post-bleaching confocal images of a representative cell at the indicated channels. Further right are calculated FRET efficiency images (pseudo-color; the yellow to purple spectrum denotes strong to weak FRET) and the differential interference contrast (DIC) images. Rightmost are bar graphs summarizing the FRET efficiencies as mean ± SEM, n > 25 cells from 3 independent experiments. Scale bars, 10 μm. (C) Same as (B) except replacing PD-L1 with PD-L2. (D) On the left is a cartoon depicting an LUV FRET assay for probing PD-L1:CD80 cis -interaction and atezolizumab (Atezo) effects. SC505 (donor) labeled SNAP-PD-L1-His was pre-bound to LUVs via DGS-NTA-Ni. Subsequently added TMR (acceptor) labeled SNAP-CD80-His bound to the LUVs and interacted with PD-L1 in cis , causing FRET and SC505 quenching (black trace). On the right are time courses of normalized SC505 fluorescence under the indicated conditions. Color coding is as follows: blue, same as black except plus atezolizumab; magenta, same as black except using TMR*CD80 lacking a His tag; orange, same as black except replacing PD-L1 with PD-L2; gray, same as black except presenting TMR*CD80 in trans . Data are representative of 3 independent replicates. Unpaired two-tailed Student’s t test: *p

    Techniques Used: Fluorescence, Expressing, Labeling, Two Tailed Test

    Cis -PD-L1 Inhibits CD80:CTLA-4 Interaction through Disrupting CD80 Homodimers (A) Representative flow-cytometry histograms of CTLA-4-huFc staining of the indicated types of Raji cells. Bound CTLA-4-huFc was labeled by AF647 anti-human IgG Fc, the MFI of which was plotted against (CTLA-4-huFc). Shown in gray are Raji (CD80 + CD86 − ) cells stained by isolated huFc domain. Means ± SEM, n ≥ 3. (B) Representative flow-cytometry histograms of CTLA-4-moFc staining of Raji (CD80 + CD86 − PD-L1-mCherry + ) cells with or without atezolizumab (Atezo) (20 μg/mL). Bound moFc was labeled by AF647 anti-mouse IgG Fc, the MFI of which was plotted against (CTLA-4-moFc). Shown in gray are atezolizumab-treated Raji (CD80 + CD86 − PD-L1-mCherry + ) cells stained by isolated moFc domain. Means ± SEM, n ≥ 3. (C) Representative flow-cytometry histograms of CTLA-4-GCN4*SC647 staining of Raji (CD80 + CD86 − PD-L1-mCherry + ) cells with or without atezolizumab and of Raji (CD80 − CD86 − ) cells with atezolizumab. MFI of SC647 was plotted against the input concentration (means ± SEM, n ≥ 3). (D) At the top are flow-cytometry histograms showing both PD-L1 and CD80 amounts on a population of Raji (CD80 wd CD86 − PD-L1-mCherry + ) cells with tight PD-L1 expression and a wide range of CD80 expression. The cells were stained with either phycoerythrin (PE) anti-CD80, PE anti-PD-L1, or PE isotype, and the 3 histograms overlaid. On the bottom is a flow-cytometry dot plot showing CTLA-4-GCN4*SC647 staining of Raji (CD80 wd CD86 − PD-L1-mCherry + ) cells with or without atezolizumab. Gray dots correspond to control signals of unstained cells. CD80 + cells were gated by the vertical dash line, determined by the mGFP signal of parental Raji (CD80 − CD86 − ) cells. (E) A FRET assay probing CD80:CD80 homodimerization on cell membranes. In the first row, the leftmost cartoon depicts a HEK293T cell expressing SNAP-CD80, with a subpopulation labeled with SS549 (donor) and the rest labeled with SSAF647 (acceptor). On the immediate right are pre- and post-bleaching confocal images of a representative cell. Further on the right is the calculated pseudo-color FRET efficiency image (yellow to purple spectrum denotes strong to weak FRET) and the DIC image. The second and third rows are the same as the first row except replacing SNAP-CD80 with SNAP-CD80 (I92R) or with SNAP-CD86. The fourth row is the same as the first row except with co-expressed unlabeled PD-L1. The fifth row is the same as fourth row except in the presence of atezolizumab. The bar graph summarizes the FRET efficiencies as mean ± SEM, n > 22 cells from 3 independent experiments. Scale bars, 10 μm. (F) An LUV FRET assay for probing CD80:CD80 homodimerization and PD-L1 effects. Shown is a representative time course of normalized FI of LUV-bound SC505*CD80-His, challenged by TMR*CD80-His and then by indicated concentrations of unlabeled PD-L1-His, with or without atezolizumab (Atezo) (20 μg/mL). (G) An LUV FRET assay showing that a single point mutation in CD80 disrupts both CD80:CD80 homodimerization and PD-L1:CD80 heterodimerization. Each indicated SC505 (energy donor)-labeled protein was pre-coupled to DGS-NTA-Ni containing LUVs through its His-tag, and challenged with TMR (energy acceptor)-labeled proteins as indicated. Shown are representative time courses of 3 independent replicates. (H) Representative TIRF images of Raji (CD80-mGFP + CD86 − PD-L1-SNAP + . Unpaired two-tailed Student’s for genotypes of cells related to this figure.
    Figure Legend Snippet: Cis -PD-L1 Inhibits CD80:CTLA-4 Interaction through Disrupting CD80 Homodimers (A) Representative flow-cytometry histograms of CTLA-4-huFc staining of the indicated types of Raji cells. Bound CTLA-4-huFc was labeled by AF647 anti-human IgG Fc, the MFI of which was plotted against (CTLA-4-huFc). Shown in gray are Raji (CD80 + CD86 − ) cells stained by isolated huFc domain. Means ± SEM, n ≥ 3. (B) Representative flow-cytometry histograms of CTLA-4-moFc staining of Raji (CD80 + CD86 − PD-L1-mCherry + ) cells with or without atezolizumab (Atezo) (20 μg/mL). Bound moFc was labeled by AF647 anti-mouse IgG Fc, the MFI of which was plotted against (CTLA-4-moFc). Shown in gray are atezolizumab-treated Raji (CD80 + CD86 − PD-L1-mCherry + ) cells stained by isolated moFc domain. Means ± SEM, n ≥ 3. (C) Representative flow-cytometry histograms of CTLA-4-GCN4*SC647 staining of Raji (CD80 + CD86 − PD-L1-mCherry + ) cells with or without atezolizumab and of Raji (CD80 − CD86 − ) cells with atezolizumab. MFI of SC647 was plotted against the input concentration (means ± SEM, n ≥ 3). (D) At the top are flow-cytometry histograms showing both PD-L1 and CD80 amounts on a population of Raji (CD80 wd CD86 − PD-L1-mCherry + ) cells with tight PD-L1 expression and a wide range of CD80 expression. The cells were stained with either phycoerythrin (PE) anti-CD80, PE anti-PD-L1, or PE isotype, and the 3 histograms overlaid. On the bottom is a flow-cytometry dot plot showing CTLA-4-GCN4*SC647 staining of Raji (CD80 wd CD86 − PD-L1-mCherry + ) cells with or without atezolizumab. Gray dots correspond to control signals of unstained cells. CD80 + cells were gated by the vertical dash line, determined by the mGFP signal of parental Raji (CD80 − CD86 − ) cells. (E) A FRET assay probing CD80:CD80 homodimerization on cell membranes. In the first row, the leftmost cartoon depicts a HEK293T cell expressing SNAP-CD80, with a subpopulation labeled with SS549 (donor) and the rest labeled with SSAF647 (acceptor). On the immediate right are pre- and post-bleaching confocal images of a representative cell. Further on the right is the calculated pseudo-color FRET efficiency image (yellow to purple spectrum denotes strong to weak FRET) and the DIC image. The second and third rows are the same as the first row except replacing SNAP-CD80 with SNAP-CD80 (I92R) or with SNAP-CD86. The fourth row is the same as the first row except with co-expressed unlabeled PD-L1. The fifth row is the same as fourth row except in the presence of atezolizumab. The bar graph summarizes the FRET efficiencies as mean ± SEM, n > 22 cells from 3 independent experiments. Scale bars, 10 μm. (F) An LUV FRET assay for probing CD80:CD80 homodimerization and PD-L1 effects. Shown is a representative time course of normalized FI of LUV-bound SC505*CD80-His, challenged by TMR*CD80-His and then by indicated concentrations of unlabeled PD-L1-His, with or without atezolizumab (Atezo) (20 μg/mL). (G) An LUV FRET assay showing that a single point mutation in CD80 disrupts both CD80:CD80 homodimerization and PD-L1:CD80 heterodimerization. Each indicated SC505 (energy donor)-labeled protein was pre-coupled to DGS-NTA-Ni containing LUVs through its His-tag, and challenged with TMR (energy acceptor)-labeled proteins as indicated. Shown are representative time courses of 3 independent replicates. (H) Representative TIRF images of Raji (CD80-mGFP + CD86 − PD-L1-SNAP + . Unpaired two-tailed Student’s for genotypes of cells related to this figure.

    Techniques Used: Flow Cytometry, Cytometry, Staining, Labeling, Isolation, Concentration Assay, Expressing, Mutagenesis, Two Tailed Test

    9) Product Images from "Imaging PD-L1 Expression with ImmunoPET"

    Article Title: Imaging PD-L1 Expression with ImmunoPET

    Journal: Bioconjugate Chemistry

    doi: 10.1021/acs.bioconjchem.7b00631

    89 Zr-C4 can specifically detect mouse PD-L1 in tumors established in an immunocompetent background. (A) Representative coronal and transaxial PET/CT images of male C57BL/6 mice bearing subcutaneous B16 F10 tumors, a mouse model of melanoma, show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 10-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P
    Figure Legend Snippet: 89 Zr-C4 can specifically detect mouse PD-L1 in tumors established in an immunocompetent background. (A) Representative coronal and transaxial PET/CT images of male C57BL/6 mice bearing subcutaneous B16 F10 tumors, a mouse model of melanoma, show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 10-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P

    Techniques Used: Positron Emission Tomography, Mouse Assay, Injection, Blocking Assay

    89 Zr-C4 can detect pharmacologically induced PD-L1 expression changes on the tumor cell. (A) Representative coronal and transverse PET images showing the distribution of 89 Zr-C4 48 h after injection in a cohort of male nu/nu mice bearing subcutaneous H1975 xenografts and treated with vehicle, paclitaxel (Taxol), or doxorubicine. The mice were treated with 20 mg/kg paclitaxel or 2 mg/kg doxorubicine for 2 days prior to radiotracer injection. (B) Representative biodistribution data in the tumor and selected normal tissues showing that paclitaxel increases tumor PD-L1 expression levels, while doxorubicin suppresses it compared to vehicle. No impact was observed on PD-L1 expressing normal tissues like liver and spleen. (∗) P
    Figure Legend Snippet: 89 Zr-C4 can detect pharmacologically induced PD-L1 expression changes on the tumor cell. (A) Representative coronal and transverse PET images showing the distribution of 89 Zr-C4 48 h after injection in a cohort of male nu/nu mice bearing subcutaneous H1975 xenografts and treated with vehicle, paclitaxel (Taxol), or doxorubicine. The mice were treated with 20 mg/kg paclitaxel or 2 mg/kg doxorubicine for 2 days prior to radiotracer injection. (B) Representative biodistribution data in the tumor and selected normal tissues showing that paclitaxel increases tumor PD-L1 expression levels, while doxorubicin suppresses it compared to vehicle. No impact was observed on PD-L1 expressing normal tissues like liver and spleen. (∗) P

    Techniques Used: Expressing, Positron Emission Tomography, Injection, Mouse Assay

    Defining the optimal time after injection to study PD-L1 expression levels in a xenograft model. (A) Representative coronal and transaxial PET/CT images of male nu/nu mice bearing subcutaneous H1975 tumors, a human model of NSCLC , show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 30-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P
    Figure Legend Snippet: Defining the optimal time after injection to study PD-L1 expression levels in a xenograft model. (A) Representative coronal and transaxial PET/CT images of male nu/nu mice bearing subcutaneous H1975 tumors, a human model of NSCLC , show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 30-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P

    Techniques Used: Injection, Expressing, Positron Emission Tomography, Mouse Assay, Blocking Assay

    89 Zr-C4 detects PD-L1 expression levels in a PDX derived from a NSCLC patient that experienced a durable clinical response to anti-PD-1 and anti-CTLA4 therapies. (A) Transaxial CT slices showing a soft tissue lesion in the lung prior to the initiation of pembrolizumab and ipilimumab (left), and a smaller mass 3 months after the start of therapy (right). The position of the tumor is indicated with a white arrow. This patient experienced a partial response for 8 months. The PDX was derived 7 months prior to the first CT scan. (B) Small animal PET/CT data showing the biodistribution of 89 Zr-C4 in mice bearing bilateral PDX tumors in the flank. The tumors can be clearly resolved, and radiotracer uptake in abdominal tissues like the liver is observed, as expected for a large biomolecule. Mice treated with 89 Zr-C4 that was heat denatured (HD) for 10 min prior to injection show no evidence of radiotracer uptake in the tumor. (C) Biodistribution data showing the uptake of 89 Zr-C4 in the PDX tissue 48 h after injection. The uptake is higher in the tumor compared to heat denatured 89 Zr-C4 (HD) and standard reference tissues like the blood and muscle. (D) Biodistribution data acquired 48 h after injection in mice bearing subcutaneous H1975, PC3, A549, and the PDX tumors show the different degree of 89 Zr-C4 uptake in the tumors.
    Figure Legend Snippet: 89 Zr-C4 detects PD-L1 expression levels in a PDX derived from a NSCLC patient that experienced a durable clinical response to anti-PD-1 and anti-CTLA4 therapies. (A) Transaxial CT slices showing a soft tissue lesion in the lung prior to the initiation of pembrolizumab and ipilimumab (left), and a smaller mass 3 months after the start of therapy (right). The position of the tumor is indicated with a white arrow. This patient experienced a partial response for 8 months. The PDX was derived 7 months prior to the first CT scan. (B) Small animal PET/CT data showing the biodistribution of 89 Zr-C4 in mice bearing bilateral PDX tumors in the flank. The tumors can be clearly resolved, and radiotracer uptake in abdominal tissues like the liver is observed, as expected for a large biomolecule. Mice treated with 89 Zr-C4 that was heat denatured (HD) for 10 min prior to injection show no evidence of radiotracer uptake in the tumor. (C) Biodistribution data showing the uptake of 89 Zr-C4 in the PDX tissue 48 h after injection. The uptake is higher in the tumor compared to heat denatured 89 Zr-C4 (HD) and standard reference tissues like the blood and muscle. (D) Biodistribution data acquired 48 h after injection in mice bearing subcutaneous H1975, PC3, A549, and the PDX tumors show the different degree of 89 Zr-C4 uptake in the tumors.

    Techniques Used: Expressing, Derivative Assay, Computed Tomography, Positron Emission Tomography, Mouse Assay, Injection

    Related Articles

    Mouse Assay:

    Article Title: Imaging PD-L1 Expression with ImmunoPET
    Article Snippet: 89 Zr-C4 Detects Tumor Associated PD-L1 Expression in Immunocompetent Mice with Endogenous PD-1 To be useful clinically, a radiotracer targeting PD-L1 must be capable of competing with PD-1 antigen in the tumor microenvironment. .. To assess whether 89 Zr-C4 can detect mouse PD-L1 in an immunocompetent background, C57 BL/6J mice were inoculated in the flank with the PD-L1 positive mouse melanoma cell line B16 F10. .. Tumor bearing mice were treated with 89 Zr-C4 and imaged with PET/CT serially for 5 days ( A).

    Recombinant:

    Article Title: Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers
    Article Snippet: For all measurements, SPR signals in the flow cell with immobilized protein were subtracted with those in a flow cell that underwent the same manipulations but where recombinant protein was omitted, to obtain specific binding signals (response units, RU). .. For CFCA, recombinant mouse PD-L1 protein was coupled to 9920 RU, for all other measurements between 650 and 900 RU proteins were coupled. .. For all measurements and between each cycle, chips were regenerated twice with 0.5M NaCl, 15 mM NaOH, each time for 10 sec at 40 μl/min.

    Article Title: A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model
    Article Snippet: When the tumors were palpable (∼4 days later), mice were i.p. administered 400 μg purified antibodies from DPDL1E-immunized mice or 400 μg control purified antibodies from DTT-immunized mice, three times at 3-day intervals. .. ELISA for Antibody DetectionNinety-six-well plates (Corning Life Sciences, New York, USA) were coated with 100 μL of 1 μg/mL mouse PD-L1 recombinant protein (Sino Biological, Beijing, China) or DTT protein in sodium carbonate buffer (pH 9.6) overnight at 4°C. .. After washing with PBS and 0.05% Tween 20 (PBST), the plates were blocked with 3% BSA in PBST.

    Article Title: Imaging PD-L1 Expression with ImmunoPET
    Article Snippet: C4 binds weakly to mouse PD-L1 from Sino Biological Inc. (360 ± 63 nM) but does not bind to mouse PD-L1 from R & D even at high concentrations (4 μM). .. These findings may indicate that mouse PD-L1 may harbor features on cells required for C4 binding that are not present on recombinant antigen. .. Radiolabeling and in Vitro Pharmacological Assessment of C4 IgG Desferrioxamine B (DFO) is a well-established potent chelator of zirconium-89 and has been used to append 89 Zr to antibodies for both animal and human studies.

    Article Title: Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers
    Article Snippet: Peripheral blood lymphocytes were purified and used as a source to create a Nb-phage display library as described previously [ ]. .. Mouse PD-L1 reactive Nbs were identified by biopanning of this library and ELISA screenings of PEs of individual Nb clones on recombinant mouse PD-L1 protein, and sequence analysis following published protocols [ ]. .. Periplasmic extractions of small-scale culturesPEs were produced as described [ ].

    Enzyme-linked Immunosorbent Assay:

    Article Title: A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model
    Article Snippet: When the tumors were palpable (∼4 days later), mice were i.p. administered 400 μg purified antibodies from DPDL1E-immunized mice or 400 μg control purified antibodies from DTT-immunized mice, three times at 3-day intervals. .. ELISA for Antibody DetectionNinety-six-well plates (Corning Life Sciences, New York, USA) were coated with 100 μL of 1 μg/mL mouse PD-L1 recombinant protein (Sino Biological, Beijing, China) or DTT protein in sodium carbonate buffer (pH 9.6) overnight at 4°C. .. After washing with PBS and 0.05% Tween 20 (PBST), the plates were blocked with 3% BSA in PBST.

    Article Title: Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers
    Article Snippet: Peripheral blood lymphocytes were purified and used as a source to create a Nb-phage display library as described previously [ ]. .. Mouse PD-L1 reactive Nbs were identified by biopanning of this library and ELISA screenings of PEs of individual Nb clones on recombinant mouse PD-L1 protein, and sequence analysis following published protocols [ ]. .. Periplasmic extractions of small-scale culturesPEs were produced as described [ ].

    Binding Assay:

    Article Title: Imaging PD-L1 Expression with ImmunoPET
    Article Snippet: C4 binds weakly to mouse PD-L1 from Sino Biological Inc. (360 ± 63 nM) but does not bind to mouse PD-L1 from R & D even at high concentrations (4 μM). .. These findings may indicate that mouse PD-L1 may harbor features on cells required for C4 binding that are not present on recombinant antigen. .. Radiolabeling and in Vitro Pharmacological Assessment of C4 IgG Desferrioxamine B (DFO) is a well-established potent chelator of zirconium-89 and has been used to append 89 Zr to antibodies for both animal and human studies.

    Clone Assay:

    Article Title: Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers
    Article Snippet: Peripheral blood lymphocytes were purified and used as a source to create a Nb-phage display library as described previously [ ]. .. Mouse PD-L1 reactive Nbs were identified by biopanning of this library and ELISA screenings of PEs of individual Nb clones on recombinant mouse PD-L1 protein, and sequence analysis following published protocols [ ]. .. Periplasmic extractions of small-scale culturesPEs were produced as described [ ].

    Sequencing:

    Article Title: Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers
    Article Snippet: Peripheral blood lymphocytes were purified and used as a source to create a Nb-phage display library as described previously [ ]. .. Mouse PD-L1 reactive Nbs were identified by biopanning of this library and ELISA screenings of PEs of individual Nb clones on recombinant mouse PD-L1 protein, and sequence analysis following published protocols [ ]. .. Periplasmic extractions of small-scale culturesPEs were produced as described [ ].

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92
    Sino Biological mouse pd l1
    89 Zr-C4 can specifically detect mouse <t>PD-L1</t> in tumors established in an immunocompetent background. (A) Representative coronal and transaxial PET/CT images of male C57BL/6 mice bearing subcutaneous B16 F10 tumors, a mouse model of melanoma, show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 10-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P
    Mouse Pd L1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse pd l1/product/Sino Biological
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse pd l1 - by Bioz Stars, 2021-07
    92/100 stars
      Buy from Supplier

    Image Search Results


    89 Zr-C4 can specifically detect mouse PD-L1 in tumors established in an immunocompetent background. (A) Representative coronal and transaxial PET/CT images of male C57BL/6 mice bearing subcutaneous B16 F10 tumors, a mouse model of melanoma, show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 10-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P

    Journal: Bioconjugate Chemistry

    Article Title: Imaging PD-L1 Expression with ImmunoPET

    doi: 10.1021/acs.bioconjchem.7b00631

    Figure Lengend Snippet: 89 Zr-C4 can specifically detect mouse PD-L1 in tumors established in an immunocompetent background. (A) Representative coronal and transaxial PET/CT images of male C57BL/6 mice bearing subcutaneous B16 F10 tumors, a mouse model of melanoma, show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 10-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P

    Article Snippet: These findings may indicate that mouse PD-L1 may harbor features on cells required for C4 binding that are not present on recombinant antigen.

    Techniques: Positron Emission Tomography, Mouse Assay, Injection, Blocking Assay

    89 Zr-C4 can detect pharmacologically induced PD-L1 expression changes on the tumor cell. (A) Representative coronal and transverse PET images showing the distribution of 89 Zr-C4 48 h after injection in a cohort of male nu/nu mice bearing subcutaneous H1975 xenografts and treated with vehicle, paclitaxel (Taxol), or doxorubicine. The mice were treated with 20 mg/kg paclitaxel or 2 mg/kg doxorubicine for 2 days prior to radiotracer injection. (B) Representative biodistribution data in the tumor and selected normal tissues showing that paclitaxel increases tumor PD-L1 expression levels, while doxorubicin suppresses it compared to vehicle. No impact was observed on PD-L1 expressing normal tissues like liver and spleen. (∗) P

    Journal: Bioconjugate Chemistry

    Article Title: Imaging PD-L1 Expression with ImmunoPET

    doi: 10.1021/acs.bioconjchem.7b00631

    Figure Lengend Snippet: 89 Zr-C4 can detect pharmacologically induced PD-L1 expression changes on the tumor cell. (A) Representative coronal and transverse PET images showing the distribution of 89 Zr-C4 48 h after injection in a cohort of male nu/nu mice bearing subcutaneous H1975 xenografts and treated with vehicle, paclitaxel (Taxol), or doxorubicine. The mice were treated with 20 mg/kg paclitaxel or 2 mg/kg doxorubicine for 2 days prior to radiotracer injection. (B) Representative biodistribution data in the tumor and selected normal tissues showing that paclitaxel increases tumor PD-L1 expression levels, while doxorubicin suppresses it compared to vehicle. No impact was observed on PD-L1 expressing normal tissues like liver and spleen. (∗) P

    Article Snippet: These findings may indicate that mouse PD-L1 may harbor features on cells required for C4 binding that are not present on recombinant antigen.

    Techniques: Expressing, Positron Emission Tomography, Injection, Mouse Assay

    Defining the optimal time after injection to study PD-L1 expression levels in a xenograft model. (A) Representative coronal and transaxial PET/CT images of male nu/nu mice bearing subcutaneous H1975 tumors, a human model of NSCLC , show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 30-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P

    Journal: Bioconjugate Chemistry

    Article Title: Imaging PD-L1 Expression with ImmunoPET

    doi: 10.1021/acs.bioconjchem.7b00631

    Figure Lengend Snippet: Defining the optimal time after injection to study PD-L1 expression levels in a xenograft model. (A) Representative coronal and transaxial PET/CT images of male nu/nu mice bearing subcutaneous H1975 tumors, a human model of NSCLC , show that peak tumor uptake of 89 Zr-C4 occurs 48 h after injection. (B) Biodistribution data also show peak tumor uptake of the radiotracer 48 h after injection. High uptake is also observed in PD-L1 positive tissues like the liver a spleen. (C) Representative data from a blocking study acquired 48 h after injection show the tumor specific uptake of 89 Zr-C4. Blocking was performed with 30-fold excess C4. Radiotracer uptake exceeded that observed in the blood pool and muscle: (∗) P

    Article Snippet: These findings may indicate that mouse PD-L1 may harbor features on cells required for C4 binding that are not present on recombinant antigen.

    Techniques: Injection, Expressing, Positron Emission Tomography, Mouse Assay, Blocking Assay

    89 Zr-C4 detects PD-L1 expression levels in a PDX derived from a NSCLC patient that experienced a durable clinical response to anti-PD-1 and anti-CTLA4 therapies. (A) Transaxial CT slices showing a soft tissue lesion in the lung prior to the initiation of pembrolizumab and ipilimumab (left), and a smaller mass 3 months after the start of therapy (right). The position of the tumor is indicated with a white arrow. This patient experienced a partial response for 8 months. The PDX was derived 7 months prior to the first CT scan. (B) Small animal PET/CT data showing the biodistribution of 89 Zr-C4 in mice bearing bilateral PDX tumors in the flank. The tumors can be clearly resolved, and radiotracer uptake in abdominal tissues like the liver is observed, as expected for a large biomolecule. Mice treated with 89 Zr-C4 that was heat denatured (HD) for 10 min prior to injection show no evidence of radiotracer uptake in the tumor. (C) Biodistribution data showing the uptake of 89 Zr-C4 in the PDX tissue 48 h after injection. The uptake is higher in the tumor compared to heat denatured 89 Zr-C4 (HD) and standard reference tissues like the blood and muscle. (D) Biodistribution data acquired 48 h after injection in mice bearing subcutaneous H1975, PC3, A549, and the PDX tumors show the different degree of 89 Zr-C4 uptake in the tumors.

    Journal: Bioconjugate Chemistry

    Article Title: Imaging PD-L1 Expression with ImmunoPET

    doi: 10.1021/acs.bioconjchem.7b00631

    Figure Lengend Snippet: 89 Zr-C4 detects PD-L1 expression levels in a PDX derived from a NSCLC patient that experienced a durable clinical response to anti-PD-1 and anti-CTLA4 therapies. (A) Transaxial CT slices showing a soft tissue lesion in the lung prior to the initiation of pembrolizumab and ipilimumab (left), and a smaller mass 3 months after the start of therapy (right). The position of the tumor is indicated with a white arrow. This patient experienced a partial response for 8 months. The PDX was derived 7 months prior to the first CT scan. (B) Small animal PET/CT data showing the biodistribution of 89 Zr-C4 in mice bearing bilateral PDX tumors in the flank. The tumors can be clearly resolved, and radiotracer uptake in abdominal tissues like the liver is observed, as expected for a large biomolecule. Mice treated with 89 Zr-C4 that was heat denatured (HD) for 10 min prior to injection show no evidence of radiotracer uptake in the tumor. (C) Biodistribution data showing the uptake of 89 Zr-C4 in the PDX tissue 48 h after injection. The uptake is higher in the tumor compared to heat denatured 89 Zr-C4 (HD) and standard reference tissues like the blood and muscle. (D) Biodistribution data acquired 48 h after injection in mice bearing subcutaneous H1975, PC3, A549, and the PDX tumors show the different degree of 89 Zr-C4 uptake in the tumors.

    Article Snippet: These findings may indicate that mouse PD-L1 may harbor features on cells required for C4 binding that are not present on recombinant antigen.

    Techniques: Expressing, Derivative Assay, Computed Tomography, Positron Emission Tomography, Mouse Assay, Injection

    Selection of anti-mouse-PD-L1 specific Nbs ( A ) Amino acid sequence alignment of the purified Nbs C3, C7, E2 and E4. The Nb sequence includes three complementarity-determining regions (CDR 1, 2, 3; indicated in red) and four framework regions (FR1-4, indicated in black). FRs are relatively conserved but CDRs vary widely among Nbs. ( B ) Affinity/kinetics SPR study of purified Nbs interacting with immobilized His-tagged recombinant mouse PD-L1 protein. Sensorgrams of different concentrations of the Nbs are shown ( n  = 1). ( C ) Representative flow cytometry results, showing staining of unmodified HEK293T cells (grey line) or HEK293T cells lentivirally modified to express mouse PD-L1 (293T moPD-L1, red line) with mAbs specific for mouse PD-L1 or Nbs C3, C7, E4 and E2 ( n  = 3).

    Journal: Oncotarget

    Article Title: Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers

    doi: 10.18632/oncotarget.16708

    Figure Lengend Snippet: Selection of anti-mouse-PD-L1 specific Nbs ( A ) Amino acid sequence alignment of the purified Nbs C3, C7, E2 and E4. The Nb sequence includes three complementarity-determining regions (CDR 1, 2, 3; indicated in red) and four framework regions (FR1-4, indicated in black). FRs are relatively conserved but CDRs vary widely among Nbs. ( B ) Affinity/kinetics SPR study of purified Nbs interacting with immobilized His-tagged recombinant mouse PD-L1 protein. Sensorgrams of different concentrations of the Nbs are shown ( n = 1). ( C ) Representative flow cytometry results, showing staining of unmodified HEK293T cells (grey line) or HEK293T cells lentivirally modified to express mouse PD-L1 (293T moPD-L1, red line) with mAbs specific for mouse PD-L1 or Nbs C3, C7, E4 and E2 ( n = 3).

    Article Snippet: Mouse PD-L1 reactive Nbs were identified by biopanning of this library and ELISA screenings of PEs of individual Nb clones on recombinant mouse PD-L1 protein, and sequence analysis following published protocols [ ].

    Techniques: Selection, Sequencing, Purification, SPR Assay, Recombinant, Flow Cytometry, Cytometry, Staining, Modification